BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16299246)

  • 1. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
    Yip KW; Mocanu JD; Au PY; Sleep GT; Huang D; Busson P; Yeh WC; Gilbert R; O'Sullivan B; Gullane P; Bastianutto C; Liu FF
    Clin Cancer Res; 2005 Nov; 11(22):8131-44. PubMed ID: 16299246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response.
    Loriot Y; Mordant P; Brown BD; Bourhis J; Soria JC; Deutsch E
    Anticancer Res; 2010 Oct; 30(10):3869-78. PubMed ID: 21036697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer.
    Masui T; Hosotani R; Ito D; Kami K; Koizumi M; Mori T; Toyoda E; Nakajima S; Miyamoto Y; Fujimoto K; Doi R
    Surgery; 2006 Aug; 140(2):149-60. PubMed ID: 16904964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model.
    Bartholomeusz C; Itamochi H; Yuan LX; Esteva FJ; Wood CG; Terakawa N; Hung MC; Ueno NT
    Cancer Res; 2005 Sep; 65(18):8406-13. PubMed ID: 16166319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
    Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
    Mohammad R; Abubakr Y; Dan M; Aboukameel A; Chow C; Mohamed A; Hamdy N; Al-Katib A
    Clin Cancer Res; 2002 Apr; 8(4):1277-83. PubMed ID: 11948143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
    Hu Y; Bebb G; Tan S; Ng R; Yan H; Sartor JR; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Nov; 10(22):7662-70. PubMed ID: 15569999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
    Thallinger C; Wolschek MF; Maierhofer H; Skvara H; Pehamberger H; Monia BP; Jansen B; Wacheck V; Selzer E
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4185-91. PubMed ID: 15217956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 inhibitors potentiate the cytotoxic effects of radiation in Bcl-2 overexpressing radioresistant tumor cells.
    Hara T; Omura-Minamisawa M; Chao C; Nakagami Y; Ito M; Inoue T
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):517-28. PubMed ID: 15667975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.
    Hui AB; Yue S; Shi W; Alajez NM; Ito E; Green SR; Frame S; O'Sullivan B; Liu FF
    Clin Cancer Res; 2009 Jun; 15(11):3716-24. PubMed ID: 19470731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
    Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
    Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
    Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
    Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irradiation of human prostate cancer cells increases uptake of antisense oligodeoxynucleotide.
    Anai S; Brown BD; Nakamura K; Goodison S; Hirao Y; Rosser CJ
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1161-8. PubMed ID: 17637391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
    Elez R; Piiper A; Kronenberger B; Kock M; Brendel M; Hermann E; Pliquett U; Neumann E; Zeuzem S
    Oncogene; 2003 Jan; 22(1):69-80. PubMed ID: 12527909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
    Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
    Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice].
    Zhang Y; Ma Y; Lu HP; Zhou XF; Xie Y; Gao JH; Liang CS
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2073-6. PubMed ID: 19080439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.